Home > Animal Health & Nutrition > Veterinary Pharmaceuticals > Canine Arthritis Treatment Market

Canine Arthritis Treatment Market Share

Report ID: GMI8835
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Canine Arthritis Treatment Market Share

The canine arthritis treatment industry is characterized by the presence of several key players offering innovative solutions. The strategic partnerships, mergers, and acquisitions are common strategies employed by players to expand their market presence, enhance their product portfolios, and gain a competitive advantage.

Canine Arthritis Treatment Market Companies

Prominent players operating in the canine arthritis treatment industry include:

American Regent, Inc.
Bayer AG
Boehringer Ingelheim Animal Health
CEVA Santé Animale
Dechra Pharmaceuticals PLC
Elanco Animal Health
Nutramax Laboratories Veterinary Sciences, Inc.
Vetoquinol SA
VetStem, Inc.
Virbac
Zoetis Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Canine arthritis treatment industry size was worth USD 2.4 billion in 2023 and will exhibit a 4.7% CAGR between 2024 and 2032 due to the rising incidence of arthritis and related conditions in canines.

The osteoarthritis segment in the canine arthritis treatment industry will reach USD 1.4 billion by 2032, driven by the high prevalence of osteoarthritis among dogs coupled with aging population of dogs, rise in pet obesity and advancements in veterinary medicine.

North America canine arthritis treatment market recorded USD 1 billion in 2023 and will grow at 4.6% CAGR from 2024 to 2032, attributed to the growing prevalence of canine arthritis, and rise in per capita animal healthcare expenditure in the region.

Some of the key canine arthritis treatment companies are American Regent, Inc., Bayer AG, Boehringer Ingelheim Animal Health, CEVA Santé Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health, Nutramax Laboratories Veterinary Sciences, Inc., among others.